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ABSTRACT  
Objective. We assessed the diagnostic accuracy of the neurofilament light chain (NFL) protein 
in cerebrospinal fluid (CSF) in distinguishing patients with Alzheimer’s disease (AD) from 
cognitively healthy controls (HCs) and frontotemporal dementia (FTD) patients. In particular, we 
tested the discriminatory performance of CSF NFL concentration in differentiating patient groups 
stratified by biomarker profiles, independent of the severity of cognitive impairment, using a novel 
unbiased biomarker-guided descriptive classification system for AD.  
Methods. CSF NFL concentrations were examined in a multicenter cross-sectional study of 108 
participants stratified in AD pathophysiology-negative (both amyloid beta and tau) (n = 15), tau-
positive only (n = 15), amyloid beta-positive only (n = 13), AD pathophysiology-positive (n = 33), 
FTD (n = 9) patients, and HCs (n = 23), according to an innovative biomarker-based classification 
system. 
Results. CSF NFL distinguished AD pathophysiology-positive patients from HCs, tau-positive 
only patients from HCs, and AD pathophysiology-positive patients from FTD with AUROCs = 
0.77, 0.69, 0.54, respectively. 
Conclusions. CSF NFL discriminated AD pathophysiology-positive patients from HCs with fair 
diagnostic accuracy, whereas the diagnostic accuracy in differentiating tau-positive patients from 
HCs is poor. Finally, the diagnostic accuracy in distinguishing AD pathophysiology-positive 
patients from FTD is unsatisfactory.  
 
KEY WORDS: Neurofilament light chain protein; axonal degeneration; Alzheimer’s disease; 
Alzheimer’s disease pathophysiology; frontotemporal dementia; cognitive aging; mild cognitive 
impairment; biomarkers; biomarker-based diagnosis; cerebrospinal fluid. 
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INTRODUCTION 
The canonical pathophysiological hallmarks of Alzheimer’s disease (AD) are a) extracellular 
deposition of aggregated amyloid beta (Aβ - i.e. amyloid plaques), and b) intraneuronal 
accumulation of neurofibrillary tangles (NFTs)1. NFTs are primarily composed of 
hyperphosphorylated microtubule-binding protein tau (p-tau) as well as neurofilaments (NFs). NFs 
are neuron-specific heteropolymers2, mostly expressed in large-caliber myelinated axons3, and are 
key structural components of the neuronal cytoskeleton. One specific NF subunit, the neurofilament 
light chain (NFL) protein, is currently being examined as a candidate biomarker for the diagnosis of 
neurodegenerative diseases4–7. Accordingly, increased cerebrospinal fluid (CSF) concentrations of 
NFL (CSF NFL) have been detected in both clinical AD4,5 and frontotemporal dementia (FTD)6,7 
compared to healthy controls.  
The aim of this study was to assess the ability of CSF NFL to discriminate groups of cognitively 
impaired patients stratified across the AD pathophysiology spectrum via an unbiased classification 
system (i.e. independently of the degree of cognitive impairment)8. The “A/T/N” scheme employs 
three binary biomarker categories which reflect AD pathophysiology, where “A” refers to 
“amyloid-beta (Aβ) pathology”, “T” to “tau pathology”, and “N” to neurodegeneration. 
Specifically, we evaluated the diagnostic accuracy of NFL in distinguishing AD pathophysiology 
patients (i.e. patients showing decreased CSF concentrations of Aβ1-42 and increased CSF 
concentrations of total tau (t-tau) or p-tau9) as well as patients with evidence of tau pathology only, 
from cognitively healthy controls (HCs). Furthermore, we evaluated the capability of CSF NFL to 
differentiate AD pathophysiology from FTD. 
 
METHODS 
Study participants 
The research was designed as a multicenter cross-sectional study conducted retrospectively in a 
convenience series from three independent European academic expert memory clinic centers. A 
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total of 135 participants were examined; out of these individuals, 27 were excluded due to missing 
data in one or more CSF biomarkers. The remaining 108 were included in the present study: 35 
participants were recruited from the Institute of Memory and Alzheimer’s Disease (Institut de la 
Mémoire et de la Maladie d’Alzheimer, IM2A) at Pitié-Salpêtrière University Hospital in Paris 
(France), 57 from the German Center for Neurodegenerative Diseases (DZNE) in Rostock 
(Germany), and 16 from the Institute of Neuroscience and Physiology at Sahlgrenska University 
Hospital in Mölndal (Sweden). The study was conducted in accordance with the tenets of the 
Declaration of Helsinki and approved by the local Ethical Committees at each participating 
university center. All participants or their representatives gave written informed consent for the use 
of their clinical data for research purposes.  
The STARD criteria for the reporting of diagnostic test accuracy studies (available at 
http://www.equator-network.org/reporting-guidelines/stard/) were followed.  
 
Patient stratification and biomarker assessment 
Patients received either a) a clinical diagnosis of AD dementia according to the National Institute 
of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related 
Disorders Association (NINCDS–ADRDA) consensus criteria10, b) a clinical diagnosis of mild 
cognitive impairment (MCI) according to the MCI core clinical criteria of the National Institute on 
Aging-Alzheimer’s Association (NIA-AA) guidelines11, or c) a diagnosis of FTD following the 
consensus on clinical diagnostic criteria of 199812. Cognitively HCs were individuals who 
volunteered for a lumbar puncture. Inclusion criteria were the absence of neurological/psychiatric 
disease history and a Mini-Mental State Examination (MMSE) score between 27 and 30. Our 
patient population was dissected according to the A/T/N scheme, an unbiased biomarker-based 
descriptive classification system recently proposed by Jack and colleagues8. The detailed 
description of patient stratification according to the A/T/N scheme, CSF sampling, immunoassays 
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for both CSF core biomarkers and CSF NFL protein, and statistical analysis are reported in the 
Supplementary Materials. 
 
 
Statistical analysis  
Age-, sex-, and site- adjusted NFL values were compared across groups through nonparametric 
statistics, after which areas under the ROC curves (AUROCs) for all binary classification problems 
were computed through logistic regression within a Leave-One-Out Cross-Validation (LOO-CV) 
approach. The discriminatory ability of NFL to correctly allocate participants to diagnostic groups 
was categorized as follows: “excellent” (AUROC 0.90–1.00), “good” (AUROC 0.80–0.89), “fair” 
(AUROC 0.70–0.79), “poor” (AUROC 0.60–0.69), or “fail”/no discriminatory capacity (AUROC 
0.50–0.59)13. 
 
RESULTS 
Table 1 summarizes group-wise concentrations of all analytes as well as demographic and 
clinical data. Cognitively HCs (Group 1) and AD pathophysiology-negative patients (Group 2, [A-
T-N-]) were significantly younger than all other groups. Compared with HCs, CSF NFL 
concentrations were significantly higher in Group 3 [A-/T±/N+, A-/T+/N±] (P = 0.014) and Group 
5 [A+/T±/N+, A+/T+/N±] (P = 0.006). Groups 3 and 5 presented significantly higher CSF NFL 
concentrations compared to Group 2, [A-/T-/N-] (P = 0.015 and P = 0.006, respectively) and Group 
4, [A+/T-/N-] (P = 0.015 and P = 0.0016, respectively) (Figure 1A). CSF NFL differentiated 
cognitively HCs from Group 3 and Group 5 with AUROCs = 0.69 (95% CI, 0.50–0.87) (Figure 
1B) and 0.77 (95% CI, 0.64–0.89) (Figure 1C), respectively. CSF NFL distinguished between 
Group 5 and Group 6 (FTD) with AUROC = 0.54 (95% CI, 0.28–0.80) (Figure 1D). Equivalent 
results obtained when stratifying according to purely clinical diagnostic criteria are reported in the 
Supplementary Materials. 
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DISCUSSION 
Compared with HCs, we found significantly higher CSF NFL concentrations in all tau-positive 
patient categories. In turn, these patients presented significantly higher CSF NFL concentrations 
compared to AD pathophysiology-negative patients. Also, CSF NFL differentiated cognitively HCs 
from tau pathology-positive only patients with a barely fair/poor diagnostic accuracy and from AD 
pathophysiology-positive patients with a fair diagnostic accuracy.  
These findings confirm the presence of a remarkable association between NFL and the neuronal 
injury marker tau4,5. Notably, NFL is primarily expressed in large-caliber myelinated axons14, and is 
therefore assumed to be a marker of white matter disease. Increased CSF NFL concentrations are 
associated with white matter damage and other varieties of lesions in subcortical brain areas15. 
Moreover, a longitudinal study found that CSF NFL concentrations are higher in AD and MCI with 
respect to HCs, and that CSF NFL concentrations correlate with structural brain alterations and 
cognitive decline over time5. This indicates that CSF NFL is a progression marker in AD and MCI 
and suggests that large-caliber axonal disintegration is a prominent aspect of AD pathophysiology5. 
This was further substantiated in a recent comprehensive meta-analysis4.  
In addition, CSF NFL concentration observed in all tau-positive patient categories was higher 
than in Aβ pathology-positive patients. This result is supported by a pivotal study showing similar 
concentrations of CSF NFL in Aβ1-42-negative and Aβ1-42-positive individuals, as dichotomized by a 
cut-off value (CSF Aβ1-42<192pg/mL). Consequently, alterations in CSF NFL concentrations do not 
seem to be dependent on the amyloidogenic Aβ1-42 peptide5 since they are substantially correlated 
with biomarkers of neurodegeneration, such as brain atrophy, and cognitive decline16.  
In contrast to a previous study7, the ability of CSF NFL to discriminate between AD 
pathophysiology-positive patients and FTD was unsatisfactory (Figure 1D) . Additional analyses 
across a range of different neurodegenerative diseases are needed to shed more light on this aspect. 
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The study has some potential caveats that need to be reported. Because of the relatively small 
sample size, it was not possible to stratify the cohort into all groups established by the original 
A/T/N scheme8. Therefore, given that only validated core CSF biomarkers (i.e. no neuroimaging) 
were employed, MCI and AD dementia individuals were grouped into a single category 
(Supplementary Figure 1). Because of the cross-sectional nature of the study, it was not possible 
to differentiate potentially stable-MCI cases from those converting into dementia as well as to 
report on prognosis and rate of progression of cognitive impairment. Moreover, extensive 
psychometric data were not available, thus preventing the study of CSF NFL concentrations in 
relation to different cognitive measures. Additionally, the quantification of the core CSF biomarkers 
of AD was not performed in a centralized manner and, while we controlled for center effects in our 
statistical analysis, further inter-laboratory variability cannot be entirely ruled out.  
This study is largely exploratory and is a first attempt to employ NFL protein as a CSF biological 
marker for AD diagnosis by employing an original, unbiased biomarker-based system of 
classification8. Conceptually, the A/T/N dissection model addresses the need for a unifying 
approach to using biomarkers in the study of AD. Due to its unbiased nature, the A/T/N scheme 
represents a flexible model that could be employed in any framework of existing diagnostic 
criteria8. Potentially, it is expected to integrate key and novel evolving biomarkers of other relevant 
pathophysiological mechanisms belonging to the spectrum of age-related neurodegenerative 
diseases, as well as genetic or epigenetic factors.  
In conclusion, our multicenter cross-sectional study highlights the diagnostic accuracy of CSF 
protein NFL in differentiating AD pathophysiology-positive patients from HCs using an innovative 
unbiased classification system which allows a biomarker-driven stratification of patients and is 
independent of the severity of cognitive impairment.  
Additional studies are required to examine whether CSF NFL may be employed as a biological 
indicator of mechanism of action and/or target engagement or as a marker predicting progression of 
cognitive impairment in drug development studies.  
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